Tonix Presents Phase 3 TONMYA Fibromyalgia Data at IASP Congress
Tonix Pharmaceuticals presented an analysis reporting improved FIQR symptoms and function scores versus an unspecified comparator.
Related stories
Thrive Holdings to Acquire ADT for $7.6 Billion in Cash
ADT said Thrive Holdings will pay $10 a share in cash, valuing the Boca Raton home-security company at $7.6 billion.
M impact | EQUITY | Oct 29, 2026, 02:16 PM UTC
Bristol-Myers Squibb Reports Quarterly Results
The company reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 02:16 PM UTC
Shelter Pharma Gets Export Orders Worth 34.7 Million Rupees
M impact | EQUITY | Oct 29, 2026, 02:16 PM UTC
Phinia Q3 Adjusted Earnings and Revenue Rise; Shares Advance
Phinia reported higher Q3 adjusted earnings and revenue, while its shares advanced.
M impact | EQUITY | Oct 29, 2026, 02:14 PM UTC
South Electronics Reports Q3 Net Loss of 137,471 Dinars
M impact | EQUITY | Oct 29, 2026, 02:13 PM UTC
Trinity Industries Reports Lower Q3 Earnings, Higher Revenue; Maintains 2026 EPS Outlook
M impact | EQUITY | Oct 29, 2026, 02:13 PM UTC